MET and hepatocellular carcinoma: The mechanisms underlying the poor efficacy of PARPIs in HCC involve the formation of EGFR and MET heterodimer that interacts with and phosphorylates Y907 of PARP1 in the nucleus, which contributes to PARPI resistance.